Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | May 20, 2026 | May 22, 2026 |
| Endo International plcENDP · Entity 124463 | Director | June 11, 2021 | June 15, 2021 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director | May 15, 2026 | May 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date May 20, 2026 · Filed May 22, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20 | Direct | 11,538 |
Reported balance
After 2026-05-20 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F1: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 5,409 |
Reported balance
After 2026-05-20 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F3: Each restricted stock unit represents a contingent right to receive one ordinary share. F1: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
F2: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above.
F3: Each restricted stock unit represents a contingent right to receive one ordinary share.
Endo International plc
Report date June 11, 2021 · Filed June 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 100,034 |
Ending reported balance
After 2021-06-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-11 · Grant · Acquired 47,924 · Balance 124,954 F1: These ordinary shares were granted to Mr. Cooke on June 11, 2021 in consideration of his services on Endo International plc's Board of Directors. Row 2 · 2021-06-11 · Tax withholding · Disposed 24,920 · Balance 100,034 F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Mr. Cooke's tax withholding obligations on shares acquired on June 11, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares were granted to Mr. Cooke on June 11, 2021 in consideration of his services on Endo International plc's Board of Directors.
F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Mr. Cooke's tax withholding obligations on shares acquired on June 11, 2021.
PROTHENA CORP PUBLIC LTD CO
Report date May 15, 2026 · Filed May 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.76 · Expires 2036-05-15 | Direct | 27,000 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 27,000 · Balance 27,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000083 · form4.xml · derivative · entry 5 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: This award is fully vested in accordance with its terms. F4 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,207 | $36.95 | $118,498.65 |
DisclosureSEC source: 0001520262-26-000083 · form4.xml · nonDerivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,679 Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000083 · form4.xml · nonDerivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:58 UTC Amendment | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000086 · form4a.xml · derivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,409 Underlying: Ordinary Shares · 5,409 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.exercise_date: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. F1 · derivative.expiration_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.expiration_date: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:58 UTC Amendment | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,538 | $0.00 Strike: $36.98 | $0.00 |
DisclosureSEC source: 0001520262-26-000086 · form4a.xml · derivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,538 Underlying: Ordinary Shares · 11,538 shares Expires 2036-05-20 F1 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.exercise_date: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000083 · form4.xml · derivative · entry 4 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,409 Underlying: Ordinary Shares · 5,409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2027. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2027. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,538 | $0.00 Strike: $36.98 | $0.00 |
DisclosureSEC source: 0001520262-26-000083 · form4.xml · derivative · entry 3 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,538 Underlying: Ordinary Shares · 11,538 shares Expires 2036-05-20 F2 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/20/2027. Read SEC document |
| May 15, 2026 Filed May 16, 2026 01:28 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $9.76 | $0.00 |
DisclosureSEC source: 0000905148-26-002467 · form4.xml · derivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Ordinary Shares · 27,000 shares Expires 2036-05-15 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:48 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 61,200 | $0.00 Strike: $31.64 | $0.00 |
DisclosureSEC source: 0001520262-26-000008 · form4.xml · derivative · entry 4 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 61,200 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:48 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 32,113 | $34.78 | $1,116,877.29 |
DisclosureSEC source: 0001520262-26-000008 · form4.xml · nonDerivative · entry 3 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,744 F1 · kind: This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.70 to $34.91. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:48 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 29,087 | $34.34 | $998,795.22 |
DisclosureSEC source: 0001520262-26-000008 · form4.xml · nonDerivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,857 F1 · kind: This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.6923 to $34.69. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:48 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 61,200 | $31.64 | $1,936,368.00 |
DisclosureSEC source: 0001520262-26-000008 · form4.xml · nonDerivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:28 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016196 · form4.xml · derivative · entry 3 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:28 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 4,175 | $30.61 | $127,796.75 |
DisclosureSEC source: 0001127602-25-016196 · form4.xml · nonDerivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,744 Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:28 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016196 · form4.xml · nonDerivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:55 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 6,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015538 · form4.xml · derivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,142 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:55 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 13,474 | $0.00 Strike: $30.53 | $0.00 |
DisclosureSEC source: 0001127602-25-015538 · form4.xml · derivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,474 Underlying: Ordinary Shares · 13,474 shares Expires 2035-05-21 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/21/2026. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:47 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 20,183 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000905148-25-001829 · form4.xml · derivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,183 Underlying: Ordinary Shares · 20,183 shares Expires 2035-05-14 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019585 · form4.xml · derivative · entry 3 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:52 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,175 | $24.10 | $76,517.50 |
DisclosureSEC source: 0001127602-24-019585 · form4.xml · nonDerivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,906 Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019585 · form4.xml · nonDerivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,492 | $0.00 Strike: $23.40 | $0.00 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 14 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,492 Underlying: Ordinary Shares · 17,492 shares Expires 2034-05-31 F7 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 13 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,013 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:35 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0000905148-24-001532 · form4.xml · derivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2034-05-15 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2025 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 12 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 119 shares Expires not disclosed F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 254 | $30.72 Strike: $30.72 | $7,802.88 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 11 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,986 Underlying: Ordinary Shares · 254 shares Expires 2033-06-29 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 231 | $30.86 Strike: $30.86 | $7,128.66 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 10 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,785 Underlying: Ordinary Shares · 231 shares Expires 2032-07-07 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 313 | $24.24 Strike: $24.24 | $7,587.12 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 9 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,990 Underlying: Ordinary Shares · 313 shares Expires 2031-06-14 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 230 | $18.45 Strike: $18.45 | $4,243.50 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 8 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,739 Underlying: Ordinary Shares · 230 shares Expires 2030-12-02 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 256 | $16.52 Strike: $16.52 | $4,229.12 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 7 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,079 Underlying: Ordinary Shares · 256 shares Expires 2030-05-20 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 448 | $24.55 Strike: $24.55 | $10,998.40 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 6 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,848 Underlying: Ordinary Shares · 448 shares Expires 2029-05-22 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 350 | $44.75 Strike: $44.75 | $15,662.50 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 5 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,850 Underlying: Ordinary Shares · 350 shares Expires 2028-05-23 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 520 | $44.75 Strike: $44.75 | $23,270.00 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 4 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,520 Underlying: Ordinary Shares · 520 shares Expires 2028-05-23 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 425 | $53.50 Strike: $53.50 | $22,737.50 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 3 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,675 Underlying: Ordinary Shares · 425 shares Expires 2027-02-17 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 1,200 | $31.64 Strike: $31.64 | $37,968.00 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,200 Underlying: Ordinary Shares · 1,200 shares Expires 2026-02-28 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:49 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 1,102 | $69.83 Strike: $69.83 | $76,952.66 |
DisclosureSEC source: 0001127602-24-017716 · form4.xml · derivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,227 Underlying: Ordinary Shares · 1,102 shares Expires 2025-02-26 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:27 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020545 · form4.xml · derivative · entry 3 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:27 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,098 | $29.88 | $92,568.24 |
DisclosureSEC source: 0001127602-23-020545 · form4.xml · nonDerivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,977 Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:27 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020545 · form4.xml · nonDerivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:31 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019624 · form4.xml · derivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,985 Underlying: Ordinary Shares · 5,985 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:31 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 12,732 | $0.00 Strike: $31.33 | $0.00 |
DisclosureSEC source: 0001127602-23-019624 · form4.xml · derivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,732 Underlying: Ordinary Shares · 12,732 shares Expires 2033-06-29 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| May 17, 2023 Filed May 20, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $76.00 | $0.00 |
DisclosureSEC source: 0001140361-23-025832 · form4.xml · derivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2024 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| January 10, 2023 Filed Jan 13, 2023 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-23-000905 · doc1.xml · derivative · entry 3 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,000 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option would have expired in approximately one month and would have been forfeited to the extent it was not exercised on or prior to January 29, 2023. F3 · derivative.expiration_date: The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option would have expired in approximately one month and would have been forfeited to the extent it was not exercised on or prior to January 29, 2023. Read SEC document |
| January 10, 2023 Filed Jan 13, 2023 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5,000 | $52.92 | $264,608.00 |
DisclosureSEC source: 0001567619-23-000905 · doc1.xml · nonDerivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $52.28 to $53.175, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4. Read SEC document |
| January 10, 2023 Filed Jan 13, 2023 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $6.41 | $32,050.00 |
DisclosureSEC source: 0001567619-23-000905 · doc1.xml · nonDerivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-22-021514 · doc1.xml · derivative · entry 5 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option will expire in approximately two months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. F5 · derivative.expiration_date: The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option will expire in approximately two months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,887 | $61.41 | $238,705.72 |
DisclosureSEC source: 0001567619-22-021514 · doc1.xml · nonDerivative · entry 4 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $60.72 to $61.55, inclusive. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 781 | $60.08 | $46,921.00 |
DisclosureSEC source: 0001567619-22-021514 · doc1.xml · nonDerivative · entry 3 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,887 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $59.68 to $60.57, inclusive. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 332 | $58.93 | $19,564.59 |
DisclosureSEC source: 0001567619-22-021514 · doc1.xml · nonDerivative · entry 2 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,668 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $58.425 to $59.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $6.41 | $32,050.00 |
DisclosureSEC source: 0001567619-22-021514 · doc1.xml · nonDerivative · entry 1 Cooke Shane · CIK 0001524823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.